Orlistat (Orlistat) Patent Expiration, LOE Window & CMS Spending

Orlistat (Orlistat) by H2 Pharma LLC: Multi-Source Generic Molecule, 0 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorH2 Pharma LLC
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$220K
2024 Medicaid Spend$871K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel